中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Molecular recognition of niacin and lipid-lowering drugs by the human hydroxycarboxylic acid receptor 2

文献类型:期刊论文

AuthorZhu, Shengnan3,7,8; Yuan, Qingning6,7; Li, Xinzhu5; He, Xinheng7; Shen, Shiyi7; Wang, Dongxue4; Li, Junrui7; Cheng, Xi1,7; Duan, Xiaoqun3,8; Xu, H. Eric2,5,7
SourceCELL REPORTS
Issued Date2023-11-28
Volume42Issue:11Pages:19
Keyworddifferent ligands recognition ligand selectivity receptor
ISSN2211-1247
DOI10.1016/j.celrep.2023.113406
Corresponding AuthorDuan, Xiaoqun(robortduan@163.com) ; Xu, H. Eric(eric.xu@simm.ac.cn) ; Duan, Jia(duanjia@simm.ac.cn)
English AbstractNiacin, an age-old lipid-lowering drug, acts through the hydroxycarboxylic acid receptor 2 (HCAR2), a G-protein-coupled receptor (GPCR). Yet, its use is hindered by side effects like skin flushing. To address this, specific HCAR2 agonists, like MK-6892 and GSK256073, with fewer adverse effects have been created. However, the activation mechanism of HCAR2 by niacin and these new agonists is not well understood. Here, we present three cryoelectron microscopy structures of Gi-coupled HCAR2 bound to niacin, MK-6892, and GSK256073. Our findings show that different ligands induce varying binding pockets in HCAR2, influenced by aromatic amino acid clusters (W91ECL1, H1614.59, W1885.38, H1895.39, and F1935.43)from receptors ECL1, TM4, and TM5. Additionally, conserved residues R1113.36 and Y2847.43, unique to the HCA receptor family, likely initiate activation signal propagation in HCAR2. This study provides insights into ligand recognition, re-ceptor activation, and G protein coupling mediated by HCAR2, laying the groundwork for developing HCAR2-targeted drugs.
WOS KeywordNICOTINIC-ACID ; BAYESIAN-APPROACH ; GPR109A ; DISCOVERY ; IDENTIFICATION ; AGONISTS ; POTENT
Funding ProjectShanghai Institute of Materia Medica (SIMM) ; Ministry of Science and Technology (China)[2018YFA0507002] ; Shanghai Municipal Science and Technology Major Project[2019SHZDZX02] ; Shanghai Municipal Sci- ence and Technology Major Project ; CAS Strategic Priority Research Program[XDB37030103] ; National Natural Science Foundation of China[32130022] ; National Natural Science Foundation of China[82121005] ; National Natural Science Foundation of China[82373881] ; Young Elite Scientists Sponsorship Program by CAST[2022QNRC001] ; Shanghai Sailing Program[23YF1456800] ; Guangxi Science and Technology Major Project[2021AA16003]
WOS Research AreaCell Biology
Language英语
WOS IDWOS:001112089200001
PublisherCELL PRESS
源URL[http://119.78.100.183/handle/2S10ELR8/308101]  
Collection新药研究国家重点实验室
Corresponding AuthorDuan, Xiaoqun; Xu, H. Eric; Duan, Jia
Affiliation1.Hangzhou Inst Adv Study, Sch Pharmaceut Sci & Technol, Hangzhou, Peoples R China
2.ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China
3.Guilin Med Univ, Dept Pharmacol, Guilin 541004, Peoples R China
4.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan 528400, Peoples R China
5.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
6.Nanjing Univ Chinese Med, Coll Pharm, Nanjing 210023, Peoples R China
7.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
8.Macau Univ Sci & Technol, Fac Med, Sch Pharm, Macau 999078, Peoples R China
Recommended Citation
GB/T 7714
Zhu, Shengnan,Yuan, Qingning,Li, Xinzhu,et al. Molecular recognition of niacin and lipid-lowering drugs by the human hydroxycarboxylic acid receptor 2[J]. CELL REPORTS,2023,42(11):19.
APA Zhu, Shengnan.,Yuan, Qingning.,Li, Xinzhu.,He, Xinheng.,Shen, Shiyi.,...&Duan, Jia.(2023).Molecular recognition of niacin and lipid-lowering drugs by the human hydroxycarboxylic acid receptor 2.CELL REPORTS,42(11),19.
MLA Zhu, Shengnan,et al."Molecular recognition of niacin and lipid-lowering drugs by the human hydroxycarboxylic acid receptor 2".CELL REPORTS 42.11(2023):19.

入库方式: OAI收割

来源:上海药物研究所

浏览0
下载0
收藏0
其他版本

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.